Quantum BioPharma (NASDAQ: QNTM) has entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) for multiple sclerosis (MS). This agreement sets in motion formal study start-up activities following the U.S. Food and Drug Administration's clearance to proceed with the trial, signaling a major milestone in the company's efforts to bring a novel treatment to people with progressive forms of MS.
The trial will be a randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of Lucid-MS using clinical and radiological endpoints. Thermo Fisher will support study start-up and related clinical research services through its PPD Clinical Research Business, bringing substantial expertise to the execution of this complex trial. Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. This mechanism of action distinguishes Lucid-MS from existing MS therapies, which primarily modulate the immune system rather than directly protect myelin.
The significance of this announcement lies in its potential to address a significant unmet need in MS treatment. Progressive forms of MS currently have limited therapeutic options, and a neuroprotective approach could fundamentally change the treatment landscape. By advancing Lucid-MS into Phase 2, Quantum BioPharma is positioning itself at the forefront of a new therapeutic category. The involvement of Thermo Fisher's PPD business lends additional credibility and operational strength to the trial, which is expected to generate critical data on both clinical and radiological outcomes.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of Lucid-MS. Preclinical models have shown the compound to both prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. If these results translate to human trials, Lucid-MS could become a transformative therapy for MS patients.
For investors and industry observers, this agreement represents a de-risking event and a clear signal of progress. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. The full press release can be viewed at https://ibn.fm/CZH9U.
The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. For more information, visit BioMedWire or www.BioMedWire.com. The full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
